Romosozumab treatment in postmenopausal women with osteoporosis

New England Journal of Medicine

Volumn 375, Issue 16, 2016, Pages 1532-1543

  Cosman, F ^a   Crittenden, D B ^b   Adachi, J D ^b   Binkley, N ^b   Czerwinski, E ^b   Ferrari, S ^b   Hofbauer, L C ^b   Lau, E ^b   Lewiecki, E M ^b   Miyauchi, A ^b   Zerbini, C A F ^b   Milmont, C E ^b   Chen, L ^b   Maddox, J ^b   Meisner, P D ^b   Libanati, C ^b   Grauer, A ^b  

^a HELEN HAYES HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; PLACEBO; ROMOSOZUMAB; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEMORAL NECK; FEMUR FRACTURE; HIP; HUMAN; HYPEROSTOSIS; HYPERSENSITIVITY; HYPOCALCEMIA; INCIDENCE; INJECTION SITE REACTION; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OSTEOARTHRITIS; OSTEOMYELITIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK FACTOR; SPINE FRACTURE; TREATMENT DURATION; TREATMENT INDICATION; BONE REMODELING; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; OSTEOPOROSIS, POSTMENOPAUSAL; PHYSIOLOGY; SPINAL FRACTURES; SUBCUTANEOUS DRUG ADMINISTRATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOMARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DENOSUMAB; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES;

EID: 84992145944     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1607948     Document Type: Article

References (24)

1. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-7.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-95.
3. Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum 2002; 47: 651-4.
4. Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 2004; 15: 120-4.
5. Wilk A, Sajjan S, Modi A, Fan CP, Mavros P. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA. Osteoporos Int 2014; 25: 2777-86.
6. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10: 537-43.
7. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001; 68: 577-89.
8. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19: 1842-4.
9. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280: 19883-7.
10. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370: 412-20.
11. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26: 19-26.
12. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015; 386: 1147-55.
13. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164: 2024-30.
14. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137-48.
15. Beighton P, Durr L, Hamersma H. The clinical features of sclerosteosis: a review of the manifestations in twenty-five affected individuals. Ann Intern Med 1976; 84: 393-7.
16. Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 2003; 51: 364-70.
17. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci 2013; 68: 1243-51.
18. Puffer S, Torgerson DJ, Sykes D, Brown P, Cooper C. Health care costs of women with symptomatic vertebral fractures. Bone 2004; 35: 383-6.
19. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012; 23: 2239-56.
20. Zerbini CA, Szejnfeld VL, Abergaria BH, McCloskey EV, Johansson H, Kanis JA. Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos 2015; 10: 224.
21. Semënov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005; 280: 26770-5.
22. van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007; 22: 19-28.
23. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011; 6(10): e25900.
24. Ominsky MS, Niu QT, Li C, Li X, Ke HZ. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res 2014; 29: 1424-30.